Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05426525 · ClinicalTrials.gov registry record · Phase 4
Use of Empagliflozin to Treat Prediabetes
A Phase 4 study of PreDiabetes and Overweight and Obesity, sponsored by Oregon State University.
- Active
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05426525: Active Phase 4 study of PreDiabetes and Overweight and Obesity, sponsored by Oregon State University.
NCT05426525 is a Phase 4 study of PreDiabetes and Overweight and Obesity that is active but no longer recruiting, run by Oregon State University. The registered enrollment target is 60 participants, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05426525, a Phase 4 study of PreDiabetes and Overweight and Obesity, is active but no longer recruiting, sponsored by Oregon State University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall purpose of this study is to identify how empagliflozin (a drug commonly used to treat type 2 diabetes) impacts skeletal muscle metabolic health among adults with prediabetes. Our aims are to: 1) Test the ability of empagliflozin to improve regulation of glucose metabolism (i.e., blood sugar) among overweight and obese individuals at risk for diabetes, and 2) Identify mechanisms to explain how empagliflozin may improve skeletal muscle glucose metabolism. We hypothesize empagliflozin will improve regulation of glucose metabolism due to changes in whole-body and skeletal muscle metabolism (e.g., increased rates of whole-body fat oxidation, evidence of impaired skeletal muscle mitochondrial respiratory function and increased energetic stress, lower accumulation of skeletal muscle lipids and improved skeletal muscle insulin signaling compared with placebo treatment).
Primary Outcome
The glucose infusion rate to maintain glycemia during insulin clamp, using plasma enrichment of glucose isotope tracer to determine changes in rates of insulin-stimulated glucose disposal
Conditions Studied
Interventions
- DRUG Empagliflozin
- DRUG Multivitamin-Placebo
Study Locations (1)
Oregon
- Oregon State University - Corvallis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-10-13 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
What the registry record for NCT05426525 still lists
NCT05426525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin is the first listed.
NCT05426525 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT05426525 about?
NCT05426525 is a clinical study titled "Use of Empagliflozin to Treat Prediabetes". The overall purpose of this study is to identify how empagliflozin (a drug commonly used to treat type 2 diabetes) impacts skeletal muscle metabolic health among adults with prediabetes. Our aims are to: 1) Test the ability of empagliflozin to improve regulation of glucose metabolism (i.e., blood su...
What is the current status of trial NCT05426525?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2022-10-13. Estimated completion is 2026-12.
What conditions does trial NCT05426525 study?
This clinical trial studies the following conditions: PreDiabetes, Overweight and Obesity, Prediabetic State.
What interventions are being tested in trial NCT05426525?
The interventions under investigation include: Empagliflozin (DRUG), Multivitamin-Placebo (DRUG).
Who is sponsoring clinical trial NCT05426525?
This trial is sponsored by Oregon State University, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05426525 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PreDiabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05426525's enrollment target sits among peer trials
60 90th of 149 higher than 54 of 149 other PreDiabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PreDiabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
RECRUITING · Phase 4
-
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
RECRUITING · Phase 4
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans
ACTIVE NOT RECRUITING · Phase 4
-
Incretins in Impaired Fasting Glucose
COMPLETED · Phase 4
-
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI